Jefferies Group’s Vanda Pharmaceuticals VNDA Stock Holding History

Jefferies Group’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-11,000	Closed	-$173K	–	1965
2021 Q4	$173K	Sell	11,000 -13,600	-55%	-$237K	﹤0.01%	1420
2021 Q3	$422K	Buy	+24,600	New	+$431K	﹤0.01%	1286
2016 Q4	–	Sell	-100,600	Closed	-$1.67M	–	2512
2016 Q3	$1.67M	Buy	+100,600	New	+$1.35M	0.01%	1017
2016 Q1	–	Sell	-3,800	Closed	-$35K	–	2591
2015 Q4	$35K	Buy	+3,800	New	+$37.9K	﹤0.01%	2154
2014 Q4	–	Sell	-362,500	Closed	-$3.76M	–	2363
2014 Q3	$3.76M	Buy	+362,500	New	+$4.75M	0.03%	511
2014 Q1	–	Sell	-114,600	Closed	-$1.42M	–	2401
2013 Q4	$1.42M	Buy	114,600 +73,300	+177%	+$736K	0.01%	690
2013 Q3	$452K	Buy	+41,300	New	+$441K	﹤0.01%	1240

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EIP

Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Jefferies Group's VNDA Position: Q1 2022 in Review

Jefferies Group sold out of Vanda Pharmaceuticals (VNDA) in Q1 2022, closing a stake of 3,914 shares — an estimated $61.4K sold.

Jefferies Group first reported a position in VNDA in Q3 2013 and held it in 13 quarters. The position peaked at $7.72M in Q1 2015. 188 funds tracked by Wall St. Rank hold VNDA as of Q1 2022.

Jefferies Group reported no remaining Vanda Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Jefferies Group sold 3,914 Vanda Pharmaceuticals shares in Q1 2022, an estimated $61.4K.
Jefferies Group first reported a position in Vanda Pharmaceuticals in Q3 2013 and held it in 13 quarters.
Jefferies Group's Vanda Pharmaceuticals position peaked at $7.72M in Q1 2015.
188 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2022.

Based on Jefferies Group's 13F filing for Q1 2022, filed 16 May 2022.